Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

988
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
988
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical and biochemical variability in composite pheochromocytomas: a report of 3 cases.

JCEM case reports·2026
Same author

DNA double-strand break signaling induces aberrant neuronal activity.

bioRxiv : the preprint server for biology·2026
Same author

Cerebral Hypoperfusion Causes Behavioral Changes and Impairs the Rod Photoreceptor Pathway in the Retina of Aged Mice.

Cellular and molecular neurobiology·2026
Same author

Mucosal vaccination in mice provides protection from diverse respiratory threats.

Science (New York, N.Y.)·2026
Same author

Potassium-enriched salt for patients with hypertension: a Hypertension Australia and National Hypertension Taskforce of Australia Position Statement.

Journal of hypertension·2025
Same author

Transcriptional Regulation of Microglial Metabolic and Activation States by P2RY12.

Glia·2025

相关实验视频

Updated: Jun 30, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.2K

弗莱卡尼德导致了节律起重器植入物上升的捕获值.

Kevin Chee-Theng Leow1, Wooi Ye Lim2, Audrey Lee2

  • 1Department of Cardiology, Canberra Hospital, Woden, Australian Capital Territory, Australia kcleow93@gmail.com.

BMJ case reports
|March 21, 2024
PubMed
概括

弗莱卡尼德是一种抗心律失常药物,很少会增加心脏起器捕获值. 在老年患者中停用弗莱卡尼德导致了节拍器功能的改善,突出了其潜在的影响.

关键词:
节律失常可能是心律失常.心血管系统的心血管系统禁忌和预防措施节奏和电生理学.

更多相关视频

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.2K

相关实验视频

Last Updated: Jun 30, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.2K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.2K

科学领域:

  • 心脏病学 心脏病学
  • 临床药理学 临床药理学

背景情况:

  • 弗莱卡尼德是一种1c类抗心律失常药物.
  • 它被处方用于 supraventricular 和心室节律失常.
  • 升高的起器捕获值是一种罕见但已有记录的副作用.

研究的目的:

  • 报告一个与使用弗莱卡尼尼德相关的高起步器捕获值的病例.
  • 突出弗莱卡因对心脏起器功能的潜在影响,特别是在老年患者中.

主要方法:

  • 一个老年患者的病例报告,患有高血压-布拉迪综合征和心房动.
  • 患者正在服用美托普罗罗尔和弗莱卡尼尼德.
  • 植入心脏起器显示了高的捕获值.
  • 测量了flecainide水平,并停止了该药物的使用.

主要成果:

  • 检测到升高的飞胺水平 (1.1μg/mL).
  • 停止使用弗莱卡尼德药物导致心脏起器捕获值的快速改善.
  • 在停止使用弗莱卡因尼德之前,确认了适当的定位.

结论:

  • 在心脏起器植入过程中,应考虑弗莱卡尼德是提高节奏值的潜在原因.
  • 老年患者和功能障碍患者的风险更高.
  • 在这些人群中,仔细监测和考虑药物治疗是至关重要的.